Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Brands, Marion M ^a   Hoogeveen Westerveld, Marianne ^a   Kroos, Marian A ^a   Nobel, Willemieke ^a   Ruijter, George J ^a   Özkan, Lale ^a   Plug, Iris ^a   Grinberg, Daniel ^b   Vilageliu, Lluïsa ^b   Halley, Dicky J ^a   Ploeg, Ans T Van Der ^a   Reuser, Arnold J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Enzyme replacement therapy; Galsulfase; Genotype phenotype correlation; Lysosomal storage disorder; Maroteaux Lamy syndrome; Mucopolysaccharidosis; Protein processing

Indexed keywords

GALSULFASE; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; MAROTEAUX LAMY SYNDROME; MUTAGENESIS; PHENOTYPE; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; ADOLESCENT; ANTIBODY PRODUCTION; FEMALE; GENETICS; IMMUNOLOGY; INFANT; MALE; PATHOLOGY; SITE DIRECTED MUTAGENESIS;

ADOLESCENT; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; IMMUNOPRECIPITATION; INFANT; MALE; MUCOPOLYSACCHARIDOSIS VI; MUTAGENESIS, SITE-DIRECTED; N-ACETYLGALACTOSAMINE-4-SULFATASE; PHENOTYPE; RECOMBINANT PROTEINS;

EID: 84875689484     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-51     Document Type: Article

References (30)

1. Mucopolysaccharidosis VI. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S, Orphanet J Rare Dis 2010 5 5 24 10.1186/1750-1172-5-5 20385007
2. Database of the clinical phenotypes, genotypes and mutant arylsulfatase B structures in mucopolysaccharidosis type VI. Saito S, Ohno K, Sekijima M, Suzuki T, Sakuraba H, J Hum Genet 2012 57 4 280 282 10.1038/jhg.2012.6 22336888
3. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C, MPS VI Study Group, Mol Genet Metab 2008 94 4 469 475 10.1016/j.ymgme.2008.04.001 18502162
4. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ, MPS VI Phase 3 Study Group, J Pediatr 2006 148 4 533 539 10.1016/j.jpeds.2005.12.014 16647419 (Pubitemid 44419350)
5. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Swiedler SJ, Hardy K, Berger KI, Decker C, J Inherit Metab Dis 2010 33 1 51 60 10.1007/s10545-009- 9007-8 20140523
6. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Brooks DA, Kakavanos R, Hopwood JJ, Trends Mol Med 2003 9 10 450 453 10.1016/j.molmed.2003.08.004 14557058 (Pubitemid 37309647)
7. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Hollak CE, Linthorst GE, Mol Genet Metab 2009 96 1 1 3 10.1016/j.ymgme.2008.10.013 19062323
8. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, Chen YT, Rosenberg AS, Kishnani PS, Genet Med 2011 13 8 729 736 10.1097/GIM.0b013e3182174703 21637107
9. The assay of arylsulphatases A and B in human urine. Baum H, Dodgson KS, Spencer B, Clin Chim Acta 1959 4 3 453 455 10.1016/0009-8981(59)90119-6 13663253
10. Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene. Garrido E, Cormand B, Hopwood JJ, Chabas A, Grinberg D, Vilageliu L, Mol Genet Metab 2008 94 3 305 312 10.1016/j.ymgme.2008.02.012 18406185
11. Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. Hasilik A, Neufeld EF, J Biol Chem 1980 255 10 4937 4945 6989821 (Pubitemid 10049707)
12. Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ, Am J Hum Genet 1996 58 6 1127 1134 8651289 (Pubitemid 26153823)
13. Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Litjens T, Hopwood JJ, Hum Mutat 2001 18 4 282 295 10.1002/humu.1190 11668612 (Pubitemid 32916859)
14. Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia. Jurecka A, Piotrowska E, Cimbalistiene L, Gusina N, Sobczynska A, Czartoryska B, Czerska K, Ounap K, Wegrzyn G, Tylki-Szymanska A, Mol Genet Metab 2012 105 2 237 243 10.1016/j.ymgme.2011.11.003 22133300
15. Genetic studies in a cluster of mucopolysaccharidosis type VI patients in Northeast Brazil. Costa-Motta FM, Acosta AX, Abe-Sandes K, Bender F, Schwartz IV, Giugliani R, Leistner-Segal S, Mol Genet Metab 2011 104 4 603 607 10.1016/j.ymgme.2011.09.017 21996138
16. Mucopolysaccharidosis type VI: Report of two Taiwanese patients and identification of one novel mutation. Yang CF, Wu JY, Lin SP, Tsai FJ, J Formos Med Assoc 2001 100 12 820 823 11802522
17. Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Voskoboeva E, Isbrandt D, von Figura K, Krasnopolskaya X, Peters C, Hum Genet 1994 93 3 259 264 10.1007/BF00212019 8125475 (Pubitemid 24066924)
18. Attenuated mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) due to homozygosity for the p.Y210C mutation in the ARSB gene. Gottwald I, Hughes J, Stewart F, Tylee K, Church H, Jones SA, Mol Genet Metab 2011 103 3 300 302 10.1016/j.ymgme.2011.03.024 21514195
19. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Karageorgos L, Brooks DA, Pollard A, Melville EL, Hein LK, Clements PR, Ketteridge D, Swiedler SJ, Beck M, Giugliani R, Harmatz P, Wraith JE, Guffon N, Leao Teles E, Sa Miranda MC, Hopwood JJ, Hum Mutat 2007 28 9 897 903 10.1002/humu.20534 17458871 (Pubitemid 47579940)
20. Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity. Hopwood JJ, Elliott H, Muller VJ, Saccone GT, Biochem J 1986 234 3 507 514 3087346 (Pubitemid 16028371)
21. Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. Brooks DA, McCourt PA, Gibson GJ, Ashton LJ, Shutter M, Hopwood JJ, Am J Hum Genet 1991 48 4 710 719 1901688 (Pubitemid 21891615)
22. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, Wraith JE, Roberts J, Ketteridge D, Hopwood JJ, Guffon N, Sa Miranda MC, Teles EL, Berger KI, Piscia-Nichols C, Am J Med Genet A 2005 134A 2 144 150 10.1002/ajmg.a.30579 15690405 (Pubitemid 40446209)
23. Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype. Jurecka A, Golda A, Opoka-Winiarska V, Piotrowska E, Tylki-Szymanska A, Mol Genet Metab 2011 104 4 695 9 10.1016/j.ymgme.2011.08.024 21917494
24. A catalogue of splice junction sequences. Mount SM, Nucleic Acids Res 1982 10 2 459 472 10.1093/nar/10.2.459 7063411 (Pubitemid 12151141)
25. Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. Thumler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, Link B, Mengel E, J Inherit Metab Dis 2012 35 6 1071 9 10.1007/s10545-012-9474-1 22441840
26. Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B. Arlt G, Brooks DA, Isbrandt D, Hopwood JJ, Bielicki J, Bradford TM, Bindloss-Petherbridge CA, von Figura K, Peters C, J Biol Chem 1994 269 13 9638 9643 8144552
27. Quality control in the endoplasmic reticulum. Ellgaard L, Helenius A, Nat Rev Mol Cell Biol 2003 4 3 181 191 12612637 (Pubitemid 36288040)
28. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network. Bradford TM, Litjens T, Parkinson EJ, Hopwood JJ, Brooks DA, Biochemistry 2002 41 15 4962 4971 10.1021/bi0121149 11939792 (Pubitemid 34298664)
29. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Brands MM, Oussoren E, Ruijter GJ, Vollebregt AA, van den Hout HM, Joosten KF, Hop WC, Plug I, van der Ploeg AT, Mol Genet Metab 2013 10.1016/j.ymgme.2013.02.013
30. Fabry disease, enzyme replacement therapy and the significance of antibody responses. Deegan PB, J Inherit Metab Dis 2012 35 2 227 243 10.1007/s10545-011-9400-y 22037707